A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD ...
Supreme Court restores access to abortion pill mifepristone through telehealth, mail, and pharmacies
The Supreme Court on Monday restored broad access to the abortion pill mifepristone, blocking a ruling that had threatened to ...
The 5th Circuit’s ruling on mifepristone “is bad for health care access, and it’s also bad for innovation,” writes Grace E.
Two drugmakers asked the U.S. Supreme Court to restore mail-order access to the abortion pill mifepristone, after an appeals ...
Labs are seeing fewer applications from international students and researchers, and some doctoral students are considering ...
Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for ...
A federal appeals court on Friday ruled that mifepristone, known as the abortion pill, can be distributed only in person and ...
A rodent-borne illness is suspected of causing an outbreak aboard a cruise ship that has killed three people and sickened ...
As competition mounts in the red-hot market for weight loss drugs, France’s medicines regulator fined Novo Nordisk ...
A research letter published on Monday in JAMA Pediatrics argues that paternal mortality deserve more attention ...
"Blue zones" as a concept have strayed far and wide from their humble roots, write Shelley Wood and Eric Topol.
China is now a peer competitor in drug innovation — and it intends to stay that way on its own terms, writes Dennis Kwok.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results